An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension

Abstract Background Hereditary angioedema (HAE) is characterized by recurrent attacks of subcutaneous or submucosal edema. Attacks are unpredictable, debilitating, and have a significant impact on quality of life. Patients may be prescribed prophylactic therapy to prevent angioedema attacks. Current...

Full description

Bibliographic Details
Main Authors: Marc A. Riedl, Jonathan A. Bernstein, Timothy Craig, Aleena Banerji, Markus Magerl, Marco Cicardi, Hilary J. Longhurst, Mustafa M. Shennak, William H. Yang, Jennifer Schranz, Jovanna Baptista, Paula J. Busse
Format: Article
Language:English
Published: Wiley 2017-10-01
Series:Clinical and Translational Allergy
Subjects:
Hereditary angioedema
Lanadelumab
Monoclonal antibody
Bradykinin
Plasma kallikrein
Prophylaxis
Online Access:http://link.springer.com/article/10.1186/s13601-017-0172-9

Internet

http://link.springer.com/article/10.1186/s13601-017-0172-9

Similar Items